Sign in
Already have access? Choose your edition
Sign-in is edition-specific. New here? Start with the free brief instead of jumping straight into a trial.
Each edition has its own app, pricing, and coverage page. Use sign-in if you already have access; otherwise pick an edition and get the free daily + weekly brief first.
AI
Daily briefings on AI labs, policy, tooling, and community shifts.
Best for
- Model releases + evals
- Policy and safety narratives
- Tooling and platform shifts
Flagship sampleUnlocked today
Recent developments around Claude Code include cc+, a desktop app offering multi-session management, security features, and workflow orchestration; Claude Fl...
Crypto
Daily briefings on markets, protocols, narratives, and risk events.
Best for
- Market structure + regulation
- Security and exploit narratives
- Protocol + dev ecosystem
Flagship sampleUnlocked today
The Resolv USR stablecoin lost its peg following a critical exploit that allowed an attacker to mint approximately 80 million unbacked tokens, extracting aro...
CYBERSECURITY
Daily briefings on vulnerabilities, incidents, and threat intel.
Best for
- Vulns and advisories
- Incidents + exploit narratives
- Vendor and community disclosures
Flagship sampleUnlocked today
The US Cybersecurity and Infrastructure Security Agency (CISA) has confirmed active exploitation of a critical remote code execution vulnerability in Microso...
ENERGY
Daily briefings on the energy transition: policy, grid, storage, and markets.
Best for
- Grid + reliability narratives
- Policy + first-party data
- Storage + transition supply chain
Flagship sampleUnlocked today
Israeli strikes on Iran's South Pars gas field, the world's largest, have triggered Iranian retaliatory attacks on Qatar's Ras Laffan LNG hub, wiping out 17%...
BIOTECH
Daily briefings on clinical, regulatory, and R&D updates from public sources.
Best for
- Clinical + regulatory narratives
- Research + preprints
- Funding + market updates
Flagship sampleUnlocked today
Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance...